B cell and T cell immunity in the female genital tract: Potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells

Clinical Microbiology and Infection

Volumn 18, Issue SUPPL. 5, 2012, Pages 117-122

  Anjuere F ^a,b   Bekri, S ^a,b   Bihl, F ^a,b   Braud, V M ^a,b   Cuburu, N ^c   Czerkinsky, C ^d   Hervouet, C ^e   Luci, C ^a,b  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d International Vaccine Institute   (South Korea)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dendritic cells; Genital immunity; Mucosal vaccines; Natural killer cells; Tissue associated memory T cells

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; RECOMBINANT VACCINE; VACCINE; VACCINIA VACCINE;

ANTIBODY RESPONSE; CELL FUNCTION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; EFFECTOR CELL; FEMALE GENITAL SYSTEM; HUMAN; HUMORAL IMMUNITY; MEMORY; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; VACCINATION; VACCINIA VIRUS; VAGINA MUCOSA;

EID: 84867403716     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2012.03995.x     Document Type: Review

References (57)

1. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012; 25: 215-222.
2. Frazer IH, Lowy DR, Schiller JT. Prevention of cancer through immunization: prospects and challenges for the 21st century. Eur J Immunol 2007; 37 (Suppl 1): S148-S155.
3. Day PM, Kines RC, Thompson CD et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010; 8: 260-270.
4. Koup RA, Douek DC. Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 2011; 1: a007252.
5. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011; 29: 6191-6218.
6. Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 2010; 10: 699-711.
7. Czerkinsky C, Anjuere F, McGhee JR et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol Rev 1999; 170: 197-222.
8. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 4 (Suppl): S45-S53.
9. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996; 184: 1879-1890.
10. Anjuere F, Czerkinsky C. Mucosal immunity and vaccine development. Med Sci (Paris) 2007; 23: 371-378.
11. Czerkinsky C, Holmgren J. Topical immunization strategies. Mucosal Immunol 2010; 3: 545-555.
12. Harandi AM, Medaglini D. Mucosal adjuvants. Curr HIV Res 2010; 8: 330-335.
13. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65: 1387-1394.
14. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998; 66: 514-520.
15. Cuburu N, Kweon MN, Hervouet C et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009; 183: 7851-7859.
16. Rosenthal KL, Gallichan WS. Challenges for vaccination against sexually transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin Immunol 1997; 9: 303-314.
17. Del Campo J, Lindqvist M, Cuello M et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant GD protein confers protective immunity against genital herpes in mice. Vaccine 2010; 28: 1193-1200.
18. Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J. Sublingual vaccination. Hum Vaccin 2011; 7: 110-114.
19. Kweon MN. Sublingual mucosa: a new vaccination route for systemic and mucosal immunity. Cytokine 2011; 54: 1-5.
20. Hervouet C, Luci C, Cuburu N et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 2010; 28: 5582-5590.
21. Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34: 269-280.
22. Carmichael JR, Pal S, Tifrea D, de la Maza LM. Induction of protection against vaginal shedding and infertility by a recombinant chlamydia vaccine. Vaccine 2011; 29: 5276-5283.
23. Marks E, Tam MA, Lycke NY. The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection. PLoS Pathog 2010; 6: e1001179.
24. Li Z, Zhang M, Zhou C, Zhao X, Iijima N, Frankel FR. Novel vaccination protocol with two live mucosal vectors elicits strong cell-mediated immunity in the vagina and protects against vaginal virus challenge. J Immunol 2008; 180: 2504-2513.
25. + T(rm) cells providing global skin immunity. Nature 2012; 483: 227-231.
26. Tang VA, Rosenthal KL. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J Reprod Immunol 2010; 87: 39-44.
27. Kupper TS. Old and new: recent innovations in vaccine biology and skin T cells. J Invest Dermatol 2012; 132(3 Pt 2): 829-834.
28. Lawson LB, Norton EB, Clements JD. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011; 23: 414-420.
29. + dendritic cells: towards the design of novel vaccine adjuvants? Expert Rev Vaccines 2011; 10: 159-161.
30. Mora JR, Bono MR, Manjunath N et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003; 424: 88-93.
31. Sigmundsdottir H, Butcher EC. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat Immunol 2008; 9: 981-987.
32. + IgA plasma cells following mucosal vaccination via estrogen control. J Immunol 2011; 187: 3044-3052.
33. 7) integrin expression by CD8 T cells in blood as a surrogate marker to predict cervical T cell responses in the female genital tract during HIV infection. Clin Immunol 2011; 141: 143-151.
34. Iijima N, Linehan MM, Saeland S, Iwasaki A. Vaginal epithelial dendritic cells renew from bone marrow precursors. Proc Natl Acad Sci U S A 2007; 104: 19061-19066.
35. Hervouet C, Luci C, Rol N et al. Langerhans cells prime IL-17-producing T cells and dampen genital cytotoxic responses following mucosal immunization. J Immunol 2010; 184: 4842-4851.
36. + T cell crosspriming in vivo. Immunity 2006; 24: 191-201.
37. Anjuere F, Luci C, Lebens M et al. In vivo adjuvant-induced mobilization and maturation of gut dendritic cells after oral administration of cholera toxin. J Immunol 2004; 173: 5103-5111.
38. Luci C, Hervouet C, Rousseau D, Holmgren J, Czerkinsky C, Anjuere F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 2006; 176: 2749-2757.
39. Lee HK, Zamora M, Linehan MM et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J Exp Med 2009; 206: 359-370.
40. + type. J Immunol 2011; 187: 4411-4415.
41. + dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005; 202: 1063-1073.
42. + T cell response and mucosal protection from viral challenge. J Virol 2011; 85: 8316-8327.
43. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "L'union fait la force". Blood 2005; 106: 2252-2258.
44. Luci C, Tomasello E. Natural killer cells: detectors of stress. Int J Biochem Cell Biol 2008; 40: 2335-2340.
45. + T cell priming in the absence of NK cells leads to enhanced memory responses. J Immunol 2011; 186: 3304-3308.
46. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012; 481: 394-398.
47. + T-cell immunity. Proc Natl Acad Sci U S A 2012; 109: 1210-1215.
48. Narni-Mancinelli E, Jaeger BN, Bernat C et al. Tuning of natural killer cell reactivity by NKP46 and helios calibrates T cell responses. Science 2012; 335: 344-348.
49. Andrews DM, Estcourt MJ, Andoniou CE et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med 2010; 207: 1333-1343.
50. + cell populations in gut and skin. Nat Immunol 2009; 10: 75-82.
51. Luci C, Gaudy-Marqueste C, Rouzaire P et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br J Dermatol 2012; 166: 789-796.
52. Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457: 722-725.
53. Ashkar AA, Rosenthal KL. Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection. J Virol 2003; 77: 10168-10171.
54. Thapa M, Kuziel WA, Carr DJ. Susceptibility of CCR5-deficient mice to genital herpes simplex virus type 2 is linked to NK cell mobilization. J Virol 2007; 81: 3704-3713.
55. Hall LJ, Clare S, Dougan G. NK cells influence both innate and adaptive immune responses after mucosal immunization with antigen and mucosal adjuvant. J Immunol 2010; 184: 4327-4337.
56. Middendorp S, Nieuwenhuis EE. NKT cells in mucosal immunity. Mucosal Immunol 2009; 2: 393-402.
57. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009; 182: 6435-6443.